The genetic defect leading to cholesteryl ester storage disease (CESD) has been determined in a 12-yr-old patient. 
Introduction
The genetic defect leading to cholesteryl ester storage disease (CESD) has been determined in a 12-yr-old patient. Lysosomal acid lipase (LAL) activity in cultured skin fibroblasts was reduced to -9% of control fibroblasts. Plasma cholesterol (255 mg/dl) and LDL-cholesterol (215 mg/dl) were elevated whereas HDL-cholesterol was reduced (19 mg/dl). Triglycerides were moderately elevated (141 mg/dl). There were no clinical abnormalities with the exception of hepatosplenomegaly. Both parents have reduced LAL activity in white blood cells. PCR analysis of the LAL mRNA from the propositus revealed a single slightly smaller mRNA species in skin fibroblasts as well as in leukocytes. The mother of the patient and his older brother had two mRNA species: one of normal size and one of the same size as the propositus. The father has a LAL mRNA of normal size only. Sequence analysis of a PCRamplified cDNA fragment showed a 72-bp in-frame deletion resulting in the loss of the codons for amino acids 254-277. Analysis of genomic DNA revealed that the 72 bp represent an exon, indicating that the deletion in the mRNA is caused by defective splicing. Sequence analysis of the patient's genomic DNA revealed a G -* A substitution in the last nucleotide of the 72-bp exon in one of his alleles. The mutant allele was shown to cosegregate with the truncated mRNA in the pedigree, providing further evidence that the G -> A substitution causes aberrant splicing and exon skipping. No normal-sized mRNA is detectable in the propositus even though he is not homozygous for the splice site mutation. This can be only accounted for by assuming that he is a compound heterozygote with a null allele inherited from his father. In summary, the data presented provide evidence that deletion of the codons for amino acids 254-277 in the LAL mRNA in combination with a null allele cause the clinical expression of CESD in our (3) (4) (5) (6) . CESD is more benign and may not be detected until adulthood. Lipid deposition is widespread although hepatomegaly may be the only clinical organ manifestation. Adrenal calcification is rare. Hyperbetalipoproteinemia is common in CESD, and premature atherosclerosis may be severe, whereas patients with WD usually succumb to liver failure in infancy before vascular changes have had a chance to become manifest. It is not known whether WD and CESD are only different expressions of defects in the LAL gene or represent defects in different genes.
LAL activity may be relevant in the pathogenesis ofarteriosclerosis. In freshly isolated mononuclear cells from patients with premature coronary heart disease (7) or arteriosclerosis of the carotid arteries (8) and patients with familial hypercholesterolemia and familial combined hyperlipidemia, (9) LAL activity was significantly reduced compared to cells from agematched controls. Some forms of hypertension may also impair aortic wall LAL activity (1O, 1 1).
Diagnosis of CESD and WD is still based on the clinical picture combined with the demonstration ofLAL deficiency in cultured skin fibroblasts, leukocytes, or other tissues (2) . The LAL gene is located on chromosome 10 ( [12] [13] [14] . Recently the full-length cDNA has been cloned ( 15 ( 17) .
Reverse transcription/polymerase chain reaction (RT/PCR). First-strand cDNA was synthesized from total RNA by oligo dT priming, using a commercially available kit (Promega Corp., Madison, WI) according to the instructions of the manufacturer. The protein coding sequence and the noncoding region were amplified by overlapping PCR using a series of synthetic oligonucleotide primers (see also The oligonucleotide pairs were used for amplifying a 1.2-kb and a 176-bp fragment from genomic DNA containing three exon intron transitions and the complete 72-bp exon. The PCR conditions were identical to those described for cDNA amplification except that the hybridization temperature was 55°C and the final MgC12 concentration was 2.5 mM. For each PCR reaction 1 gg of genomic DNA was used as a template.
Direct DNA sequencing ofPCR products. PCR products were separated by electrophoresis through 1.5% agarose gels. The amplified DNA was extracted from the gel using a glass powder method (Geneclean II, BIO 101, Inc., San Diego, CA). Single-stranded template DNA was generated by asymmetric PCR using 40 ng of the purified PCR product from the first amplification as a template. The DNA was reamplified for 35 cycles in the presence of one primer to generate single-strand DNA. The single stranded DNA (1-2 Ag) was purified using the Diagen Ml 3 DNA purification kit (Diagen, Hilden, FRG) following the protocol of the manufacturer. DNA sequencing was carried out by the dideoxy chain terminating method ( 1 8) using [a 35S]-dATP as radioactive label and the modified T7 DNA polymerase (Sequenase 2.0, United States Biochemical Corp., Cleveland, OH).
Cloning and sequencing ofamplified genomic DNA. PCR products obtained from genomic DNA as described above were blunt end ligated into the HincIl site of the plasmid pUC18 (19) . Plasmid DNA was sequenced using the Sequenase 2.0 kit, according to the instructions of the manufacturer. The sequence was analyzed on an automatic DNA sequencer (Automated Laser Fluorescence, Pharmacia, Uppsala, Sweden).
Isolation ofgenomic clonesfor LAL. A commercially available human genomic library in lambda FIX II (Stratagene, Inc., La Jolla, CA) was screened with the 1.2-kb cDNA fragment containing the coding sequence of LAL from positions 21 to 1265 (15) . Eight positive lambda clones were purified and digested with Xbal for Southern blot analysis ( 19) . For sequencing fragments were subcloned into pUC 18.
Measurement ofLAL activity. Enzyme activity was measured from cell lysates of skin fibroblasts and white blood cells as described previously (20 Plasma cholesterol and LDL-cholesterol levels were significantly elevated while HDL-cholesterol was reduced (Table I) . Plasma triglycerides were only slightly elevated. All other clinical and laboratory examinations were normal.
LAL activity was measured in the patient's fibroblasts. The residual activity was 9% compared to controls. The enzyme activity was also measured in leukocytes isolated from the patient's family. All members of the family have reduced activity (Table II) . In leukocytes the patient's residual LAL activity was found to be only 2% of control activity.
Analysis ofthe LAL mRNA by RT/PCR. Total RNA was isolated from cultured skin fibroblasts or from white blood cells of pedigree members, reverse transcribed into cDNA, and the coding and noncoding regions of the LAL mRNA were amplified using the primer pairs LAC 1 /LAC2 and LAC3 /LAC4, respectively. The PCR product of the coding sequence of the patient was smaller in size compared to controls (Fig. 1, lanes I  and 2) , whereas the PCR product from the 3' nontranslated region was identical in size (data not shown). There was no detectable 5' PCR product of normal size. RNA from the patient's family was also analyzed by RT/PCR with the oligonu- Positions in the pedigree correspond to Fig. 4 .
cleotides LACI and LAC2. The results are shown in Fig. 1 (lanes 4-7). His mother and older brother had both the deleted and normal-sized mRNA, and his father only a normal-sized mRNA. The mRNA ofthe 3-yr-old brother (11-3) could not be analyzed, because the blood obtained was only sufficient for determination of enzyme activity. The parents denied consent to take another blood sample for RNA analysis. Sequencing ofcoding region ofLAL. Direct sequencing of the region of the cDNA where the deletion was expected was accomplished by asymmetric PCR using primers LAC 1 / LAC2. Sequence analysis revealed a 72-bp in-frame deletion in the patient's cDNA (Fig. 2) , resulting in the loss of 24 amino acids ofthe protein (position 254-277). In addition, the cDNA sequence of the propositus has a C instead of a T at position 937 when compared to the published cDNA (Fig. 2, right) . This T -) C transition affects the third position of the codon Ala278 and does not change the predicted amino acid sequence. When the whole coding region of the LAL mRNA of the propositus (bases 21-1265) was sequenced after subcloning ofthe PCR fragment into pUC 18, no further differences to the published sequence ( 15) Genomic analysis. To determine whether the 72-bp deletion is on the gene level or is due to defective RNA splicing, genomic DNA from the pedigree and the control were digested with Xbal and Southern blots were hybridized with a 1.2-kb cDNA probe containing the coding sequence ofLAL. Since the fragment deleted from the mRNA contains an Xbal site, one Figure 2 . Left: Total RNA from a patient's (11-2) fibroblasts was reverse transcribed, amplified with primers LACI and LAC2, and analyzed by direct sequencing as described in Methods. - would expect an altered restriction fragment pattern, if the deletion was present on the genomic level. No differences in the patterns of the propositus, the other family members, and a control were detectable, indicating the presence ofthe Xbal site in the propositus's DNA (data not shown). This was taken as evidence that the defect is caused by defective splicing of the hnRNA.
To further elucidate the genetic defect genomic DNA was amplified. Primers LAC 5 /LAC6 allowed the amplification of a 1.2-kb fragment containing the entire 5'-intron and two exon intron transitions (Fig. 3) . PCR amplification of the 3'-intron using primers within the 72-bp exon and the adjacent cDNA sequence expected to be located in the downstream exon was not successful, indicating the presence of a very large intron. Therefore, a genomic lambda library (8 X 105 clones) was screened with the LAL cDNA as a probe to isolate genomic clones. Eight genomic clones were identified and further characterized by Southern blotting. A 650-bp Xbal fragment, which hybridized with oligonucleotide LAC6, was sequenced. It contained the complete 72-bp exon and part of the 3' flanking intron (intron B). From the intron sequence an oligonucleotide (LAC8) was synthesized and used for amplification ofthe 3' exon intron junction in the patient's DNA (Fig. 3) . By sequencing cloned PCR fragments a G -. A substitution was detected in the last position of the 72-bp exon. 7 of 16 clones sequenced had an A and 9 a G in this position, indicating heterozygosity (data not shown). In the patient's genomic DNA two additional exon intron transitions in the vicinity of the 72-bp exon were analyzed ( Fig. 3 and Table III ). With the exception ofthe point mutation there were no other differences between the wild-type sequence and the patient's DNA. Analysis of genomic DNA of the patient's family using the same approach as for the propositus revealed that the father carries two alleles with the wild-type sequence (G allele) around the (2) . Analysis of RNA from fibroblasts and white blood cells showed that the patient had only one mRNA for LAL that lacked 72 bp compared to the wild-type mRNA. In that this deletion contains a Xbal site, it was possible to distinguish between a deletion in the genome and a posttranscriptional event, e.g., a splicing defect. Southern blotting showed that the Xbal site is present in the genome of the patient and his mother who transmitted the defective allele. In fact, the deleted fragment could be shown by genomic sequencing to represent an entire exon, indicating that exon skipping leads to truncation of the mRNA. When the 5' and 3' splice junctions of the exons were sequenced, the only difference to the wild-type sequence was a G --A transition in the last base of the 72-bp exon of the patient. This G -> A transition was also detected in the mother's and older brother's genome, whereas it is not present in the father's DNA. This demonstrates cosegregation of the mutant allele and the truncated mRNA and is evidence for a G-A transition at splice junction null allele Figure 4 . Pedigree of the CESD family described in this study. The causal relationship between the two. In the literature five more cases of a G --A transition in the last base of an exon leading to exon skipping have been reported (22) (23) (24) (25) .
Genomic sequencing proved that the patient is heterozygous at the LAL locus. One allele has the G --A transition, whereas the other has the wild-type sequence. Thus, one would expect, in addition to the truncated mRNA, a normal-sized mRNA, which is not the case. There are only two possible explanations for this observation. There might be another splicing defect leading to a similar truncation of the mRNA. This is highly unlikely, because the splice junctions have been sequenced and are normal. In addition, one would expect to detect a truncated mRNA in the father in this case. The second, much more likely, explanation is the presence of a null allele which is not expressed or leads to a highly unstable mRNA. The assumption of the presence of a null allele would explain the pedigree data including the reduced LAL activity in the leukocytes of the patient's father. To solve this matter conclusively, we are currently in the process of analyzing the promoter region ofthe LAL gene. Fig. 4 summarizes the proposed pattern of inheritance at the LAL locus in the family presented here.
In that skipping of the 72-bp exon does not disrupt the reading frame, the mutant mRNA was expected to be translated into a truncated protein missing 24 amino acid residues encoded by the 72-bp exon. The deletion does not include the putative active esterase site with the consensus sequence for serine esterases G-X-S-X-G. In addition, it does not affect potential sites for N-glycosylation. No 
